The Israeli firm recently announced the results of a multicenter study of its Bladder EpiCheck test in addition to netting €2.5 million in EU funding to develop a lung cancer assay.
The San Diego-based company is ramping up efforts to market its handheld molecular influenza test in anticipation of the upcoming flu season.
The Cobas HPV Test is now approved for use as a primary screening test with BD's SurePath and Hologic's ThinPrep PreservCyt Solution.
The system is for high-throughput testing in central labs and the firm plans additional assays for infectious and sexually transmitted diseases.
FIND is granting an award to Altona Dx, Cepheid, and the Bernhard Nocht Institute to develop an assay for Lassa virus. It also signed an MOU with the UK government to combat antimicrobial resistance.
The kit, designed to rapidly detect 16 beta-lactam and carbapenem-resistant pathogen targets, was CE marked last month.
The newly independent firm will continue to invest in diagnostics by bringing its menu of PCR tests for infectious diseases to the US and other markets, among other objectives.
Despite the astronomical costs, it may prove challenging to reverse course and discontinue Zika testing according to a commentary article accompanying a NEJM study.
The Dublin-based company also aims to raise up to €5 million this year to support additions to its R&D and sales and marketing teams.
The company unveiled forthcoming products for high-throughput molecular testing, diagnostic lab informatics, and microbiology automation.